
Alynlam secures fomer Pfizer head
pharmafile | July 7, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Pfizer, alynlam, amy schulman
US biotech firm Alynlam has elected Pfizer’s former executive VP and general counsel Amy Schulman to its board of directors.
Schulman’s role was as the business unit lead for Pfizer’s consumer healthcare department, and she currently serves on the faculty of Harvard Business School as a senior lecturer.
“Amy is a recognised leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our board as we continue to build Alnylam as a leading biotechnology company,” says John Maraganore, chief executive of Alnylam.
Schulman joined Pfizer in 2008 as general counsel and saw the company through its acquisition of Wyeth. In 2010 she became president and general manager of Pfizer’s infant formula and nutrition business. Once that business was sold to Nestlé she assumed responsibility for the consumer healthcare unit.
Last year Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer accredited her as being one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.”
“I am excited to join the Board of Alnylam, a first-in-class innovation-based biotechnology company, and a pioneer in advancing an entirely new class of high impact medicines with RNAi therapeutics,” Schulman said.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






